Infliximab (Remicade, Inflectra, Renflexis)

Infliximab (Remicade, Inflectra, Renflexis) is covered only for the listed FDA‑approved and specified off‑label compendial indications (e.g., Crohn’s, UC, RA, PsA, psoriasis, ankylosing spondylitis, uveitis, GVHD, hidradenitis suppurativa, JIA, etc.) and is not approved for uses outside those indications. Coverage requires meeting indication‑specific criteria (prior therapy trials or documented intolerance/contraindication, age limits), prescription by or consultation with the appropriate specialist, documentation of diagnosis/prior therapies/dosing, IV administration over ≥2 hours, and documented clinical response for reauthorization.

"Crohn's disease (including patients with enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or with prior ileocolonic resection)"

Sign up to see full coverage criteria, indications, and limitations.